title: Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.
abstract: The objective of this study was to investigate the influence of genetic polymorphisms in the CYP3A and CYP2C19 genes on cilostazol pharmacokinetics, with the drug being administered orally as a 50-mg single dose in healthy subjects. CYP2C19 genotypes in individuals with the CYP3A5*3/*3 genotype were associated with statistically significant differences (P < 0.05) in cilostazol pharmacokinetics parameters (apparent oral clearance (CL/F) and terminal half-life (t(1/2))). This indicates that CYP2C19 polymorphisms play an important role in the metabolism of cilostazol only in individuals with the CYP3A5*3/*3 genotype, which has low metabolic activity.
authors.affiliation: College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Korea.
authors.forename: H-D
authors.initials: HD
authors.lastname: Yoo
authors.forename: S-A
authors.initials: SA
authors.lastname: Park
authors.forename: H-Y
authors.initials: HY
authors.lastname: Cho
authors.forename: Y-B
authors.initials: YB
authors.lastname: Lee
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077407:Cilostazol; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D005787:Gene Frequency; D005838:Genotype; D006207:Half-Life; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics*; D011110:Polymorphism, Genetic / Q000235:genetics; D013777:Tetrazoles / Q000493:pharmacokinetics*; D014665:Vasodilator Agents / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A; D000077407:Cilostazol